Evidence map›Paper›PMID 25367220›Full record

ArticleProteomics2015

A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Brian G Blair, Xinyan Wu, Muhammad Saddiq Zahari, Morassa Mohseni, Justin Cidado, Hong Yuen Wong, Julia A Beaver, Rory L Cochran, Daniel J Zabransky, Sarah Croessmann and 5 more

Abstract read
In one paragraph

Article in Proteomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. HER2 missense mutations have distinct effects on oncogenic signaling and migration.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Brian G BlairThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xinyan Wu
Muhammad Saddiq Zahari
Morassa Mohseni
Justin Cidado
Hong Yuen Wong
Julia A Beaver
Rory L Cochran
Daniel J Zabransky
Sarah Croessmann
David Chu
Patricia Valda Toro
Karen Cravero
Akhilesh Pandey
Ben Ho Park
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · USJohns Hopkins Medicine · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
VACCINES--A NEW PARADIGM FOR BREAST CANCERP50CA088843 · NCI · JOHNS HOPKINS UNIVERSITY · PI DAVIDSON, NANCY ELLEN · 2000 to 2010
$27.8M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
Proteome Characterization Center: A Genoproteomics Pipeline for Cance ResearchU24CA160036 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2011 to 2016
$10.7M
Predoctoral Training Program in Human GeneticsT32GM007814 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 1985 to 2021
$10.6M
Networks, Pathways and Dynamics of Lysine ModificationU54GM103520 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BADER, JOEL S. · 2012 to 2013
$7.0M
Cooperation of Mutant TP53 and PIK3CA in Breast CarcinogensisF31CA167939 · NCI · JOHNS HOPKINS UNIVERSITY · PI CROESSMANN, SARAH E · 2013 to 2015
$88k
A novel model system for risk assessment of BRCA carriersF31CA168180 · NCI · JOHNS HOPKINS UNIVERSITY · PI COCHRAN, RORY LANDON · 2012 to 2013
$84k
NCI NIH HHS CA088843NCI NIH HHS CA167939NCI NIH HHS CA168180NCI NIH HHS CA62924NCI NIH HHS F31 CA167939NCI NIH HHS F31 CA168180NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA088843NCI NIH HHS U24 CA160036NCI NIH HHS U24CA160036NHLBI NIH HHS HHSN268201000032CNIGMS NIH HHS GM007309NIGMS NIH HHS T32 GM007309NIGMS NIH HHS T32 GM007814NIGMS NIH HHS T32 GM008752NIGMS NIH HHS U54 GM103520NIGMS NIH HHS U54GM103520
6 · The paper itself

Abstract

The PIK3CA gene encodes for the p110 alpha isoform of PI3 kinase and is one of the most frequently mutated oncogenes in human cancers. However, the mechanisms by which PIK3CA mutations activate cell signaling are not fully understood. Here we used a phosphoproteomic approach to compare differential phosphorylation patterns between human breast epithelial cells and two isogenic somatic cell knock in derivatives, each harboring a distinct PIK3CA mutation. We demonstrated differential phosphorylation patterns between isogenic cell lines containing a PIK3CA helical domain mutation (E545K) compared to cells with a PIK3CA kinase domain mutation (H1047R). In particular, the receptor tyrosine kinase, HER3, showed increased phosphorylation at tyrosine 1328 in H1047R cells versus E545K cells. Genetic studies using shRNA demonstrated that H1047R cells have a profound decrease in growth factor independent proliferation upon HER3 knock down, but this effect was attenuated in E545K cells. In addition, HER3 knock down led to reductions in both PI3 kinase and MAP kinase pathway activation in H1047R cells, but in E545K cells only PI3 kinase pathway diminution was observed. These studies demonstrate the power of using paired isogenic cell lines for proteomic analysis to gain new insights into oncogenic signal transduction pathways.

Indexed as

ProteomicsSignal TransductionBreast NeoplasmsCell LineCell Line, TumorCell ProliferationClass I Phosphatidylinositol 3-KinasesFemaleGene Expression Regulation, NeoplasticHumansMitogen-Activated Protein KinasesMutationPhosphatidylinositol 3-KinasesPhosphorylationProtein Structure, TertiaryReceptor, ErbB-3Class I Phosphatidylinositol 3-KinasesERBB3 protein, humanMitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesPIK3CA protein, humanReceptor, ErbB-3BiomedicineHER3MAP kinasePI3 kinasePIK3CA

Identifiers

PMID25367220
PMCPMC4352327
OpenAlexW2075230086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.